

LINCOCIN[®] capsules, syrup, injection (lincomycin)

1. NAME OF THE MEDICINAL PRODUCT

LINCOCIN[®]

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

LINCOCIN[®] is available as:

- LINCOCIN[®] Injection 300 mg/mL
- LINCOCIN[®] Injection 600 mg/2 mL
- LINCOCIN[®] Capsules 500 mg
- LINCOCIN[®] Syrup 250 mg/5ml

3. PHARMACEUTICAL FORM

Capsules, syrup, Solution for injection

4. CLINICAL PARTICULARS

4.1. THERAPEUTIC INDICATIONS

- LINCOCIN[®] has been shown to be effective in the treatment of the following infections when caused by susceptible strains of gram positive aerobes such as streptococci, pneumococci, and staphylococci, or by susceptible anaerobic bacteria.¹³⁻¹⁷
- Upper respiratory infections¹⁻⁹ including tonsillitis, pharyngitis, otitis media, sinusitis, scarlet fever and as adjuvant therapy for diphtheria. Effectiveness in the treatment of mastoiditis would be anticipated.
- Lower respiratory infections^{1-4,7,10-13} including acute and chronic bronchitis and pneumonia.
- Skin and soft tissue infections^{1-4,7,11,13-21} including cellulitis, furuncles, abscesses, impetigo, acne and wound infections. Conditions like erysipelas, lymphadenitis, paronychia (panaritium), mastitis and cutaneous gangrene, should, if caused by susceptible organisms, respond to lincomycin therapy.
- Bone and joint infections^{1-4,21,22} including osteomyelitis and septic arthritis.
- Septicemia^{1-4,7,10-12,13} and endocarditis^{1-4,7,10,12,23-25}. Selected cases of septicemia and/or endocarditis due to susceptible organisms have responded well to lincomycin. However, bactericidal drugs are often preferred for these infections.
- Bacillary dysentery²⁶⁻²⁸ Although *Shigella* is resistant to lincomycin *in vitro* (MIC approximately 200-400 mcg/mL), lincomycin has been effective in its treatment due to the very high levels of lincomycin attained in the bowel (approximately 3000-7000 mcg/gram of stool).

4.2. POSOLOGY AND METHOD OF ADMINISTRATION

1. Dosage in Adults

Oral Administration

- Infections due to susceptible organisms, 500 mg t.i.d. (q8h).
- More severe infections: 500 mg q.i.d. (q6h).
- For optimal absorption, it is recommended that nothing be given by mouth for a period of 1 to 2 hours before or after oral administration of lincomycin.

Intramuscular Injection

- 600 mg IM every 24 hours.
- More severe infections: 600 mg IM every 12 hours (or more often) as determined by the severity of the infection.

Intravenous Infusion

Intravenous doses are given on the basis of 1 gram of lincomycin diluted in not less than 100 mL of appropriate solution and infused over a period of not less than 1 hour. *NOTE:* Severe cardiopulmonary reactions have occurred when this drug has been given at greater than the recommended concentration and rate.

- 600 mg to 1 gram every 8 to 12 hours.
- For more severe infections these doses may have to be increased.
- In life threatening situations, daily intravenous doses of as much as 8 grams have been given.

Dilution and Infusion Rates

Dose	Volume of Diluent	Time
600 mg	100 mL	1 hr
1 gram	100 mL	1 hr
2 grams	200 mL	2 hr
3 grams	300 mL	3 hr
4 grams	400 mL	4 hr

These doses may be repeated as often as required to the limit of the maximum recommended daily dose of 8 grams of lincomycin.

2. Dosage in Children (over 1 month of age)

Oral Administration

30 mg/kg/day divided into 3 or 4 equal doses.

More severe infections: 60 mg/kg/day divided into 3 or 4 equal doses.

For optimal absorption, it is recommended that nothing be given by mouth for a period of 1 to 2 hours before or after oral administration of lincomycin.

Intramuscular Injection

10 mg/kg/day as 1 intramuscular injection.
 More severe infections: 10 mg/kg given every 12 hours or more often.

Intravenous Infusion

10 to 20 mg/kg/day, depending on the severity of the infection, may be infused in divided doses as described in the section on Dilution and Infusion rates.

3. Dosage in Patients with Diminished Hepatic or Renal Function

In patients with impaired hepatic function or impaired renal function, lincomycin's serum half-life is increased. Consideration should be given to decreasing the frequency of administration of lincomycin in patients with impaired hepatic or renal function.⁵²⁻⁵⁴

When therapy with lincomycin is required in individuals with severe impairment of renal function, an appropriate dose is 25% to 30% of that recommended for patients with normally functioning kidneys.

4. Beta-hemolytic Streptococcal Infections

Treatment should be continued for at least 10 days.

5. Incompatibilities

See section 6.2

4.3. CONTRAINDICATIONS

Lincomycin is contraindicated in patients previously found sensitive to lincomycin or clindamycin or to any other component of the product.

4.4. SPECIAL WARNINGS AND PRECAUTIONS FOR USE

The lincomycin injection formulation contains benzyl alcohol. The preservative benzyl alcohol has been associated with serious adverse events, including the “gasping syndrome”, and death in pediatric patients. Although normal therapeutic doses of this product ordinarily deliver amounts of benzyl alcohol that are substantially lower than those reported in association with the “gasping syndrome”, the minimum amount of benzyl alcohol at which toxicity may occur is not known. The risk of benzyl alcohol toxicity depends on the quantity administered and the liver and kidneys capacity to detoxify the chemical. Premature and low-birth weight infants may be more likely to develop toxicity.^{73,76}

Pseudomembranous colitis has been reported with nearly all antibacterial agents, including lincomycin, and may range in severity from mild to life-threatening. Therefore, it is important to consider the diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents.

Severe hypersensitivity reactions, including anaphylactic reactions and severe cutaneous adverse reactions (SCAR) such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), acute generalised exanthematous pustulosis (AGEP), and erythema multiforme (EM) have been reported in patients receiving lincomycin therapy. If an anaphylactic reaction or severe skin reaction occurs,

lincomycin should be discontinued and appropriate therapy should be initiated (see Section 4.8 Undesirable effects).⁹⁶

Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by *Clostridium difficile* is a primary cause of “antibiotic-associated colitis”. After the primary diagnosis of pseudomembranous colitis has been established, therapeutic measures should be initiated. Mild cases of pseudomembranous colitis usually respond to drug discontinuation alone. In moderate-to-severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and treatment with an antibacterial drug clinically effective against *Clostridium difficile* colitis.²⁹⁻⁴³

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including lincomycin, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of *C difficile*.⁵⁹⁻⁷²

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of *C. difficile* cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.⁵⁹⁻⁷²

Although lincomycin appears to diffuse into cerebrospinal fluid, levels of lincomycin in the CSF may be inadequate for the treatment of meningitis.^{44,45} Thus, the drug should not be used in the treatment of meningitis.

If lincomycin antibiotic therapy is prolonged, liver and kidney function tests should be performed.⁴⁶

The use of antibiotics may result in overgrowth of non-susceptible organisms, particularly yeasts.⁴⁷

Lincomycin should not be injected IV as a bolus but should be infused as described in section 4.2. **Posology and Method of Administration.**

4.5. INTERACTION WITH OTHER MEDICAMENTS AND OTHER FORMS OF INTERACTION

Lincomycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents.^{50,51} Therefore, lincomycin should be used with caution in patients receiving such agents.

4.6. FERTILITY, PREGNANCY AND LACTATION

Benzyl alcohol can cross the placenta. See Section 4.4. **Special Warnings and Precautions for Use.**⁷³

In humans, lincomycin crosses the placenta and results in cord serum levels about 25% of the maternal serum levels. No significant accumulation occurs in the amniotic fluid.⁵⁶ There are limited data on the use of lincomycin in pregnant women.⁹⁴ The progeny of 302 patients treated with lincomycin at various stages of pregnancy showed no increases in congenital anomalies or delayed development compared to a control group for up to 7 years after birth.⁵⁷ Lincomycin should be used during pregnancy only if clearly needed.

Lincomycin has been reported to appear in human breast milk in concentrations of 0.5 to 2.4 mcg/mL.⁴⁴

4.7. EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

No studies were conducted to determine the effect of lincomycin on ability to drive and use machines.⁹⁴

4.8. UNDESIRABLE EFFECTS

Adverse Drug Reactions

Adverse Drug Reaction Table ^{74,75}	
System Organ Class	Adverse Drug Reactions
Infections and infestations	Pseudomembranous colitis, <i>Clostridium difficile</i> colitis, vaginal infection
Blood and lymphatic system disorders	Pancytopenia, agranulocytosis, aplastic anaemia, neutropenia, leukopenia, thrombocytopenic purpura
Immune system disorders	Anaphylactic reaction, angioedema, serum sickness
Cardiac disorders	Cardio-respiratory arrest ^a
Vascular disorders	Hypotension, ^b thrombophlebitis ^c
Gastrointestinal disorders	Oesophagitis, ^d diarrhoea, nausea, vomiting, abdominal discomfort
Hepatobiliary disorders	Jaundice, liver function test abnormal
Skin and subcutaneous tissue disorders	Toxic epidermal necrolysis, ⁹⁶ Stevens-Johnson syndrome, acute generalised exanthematous pustulosis, ⁹⁶ dermatitis bullous, dermatitis exfoliative, erythema multiforme, rash, urticaria, pruritus
General disorders and administration site conditions	Injection site abscess sterile, ^e injection site induration, ^e injection site pain, ^e injection site irritation ^e
a. Rare instances have been reported after too rapid intravenous administration. b. Following parenteral administration, particularly after too rapid administration. c. Event has been reported with intravenous injection. d. Event has been reported with oral preparations. e. Reported with intramuscular injection.	

4.9. OVERDOSE

Hemodialysis or peritoneal dialysis does not effectively remove lincomycin from the blood.

5. PHARMACOLOGICAL PROPERTIES

5.1. PHARMACODYNAMIC PROPERTIES

Mode of Action:

Lincomycin is an antibiotic produced by fermentation of *Streptomyces lincolnensis*. Lincomycin inhibits bacterial protein synthesis by binding to the 50S subunit of the bacterial ribosome. Lincomycin is predominantly bacteriostatic *in vitro*. The antibacterial activity of lincomycin appears to best correlate with the length of time the concentration of active ingredient remains above the MIC of the infecting organism.⁹⁴

Mechanism of Resistance

Cross resistance between lincomycin and clindamycin is complete. Resistance in staphylococci and streptococci is most often due to methylation of specific nucleotides in the 23S RNA of the 50S ribosomal subunit, which can determine cross resistance to macrolides and streptogramins B (MLS_B phenotype).

Macrolide-resistant isolates of these organisms should be tested for inducible resistance to lincomycin/clindamycin using the D zone test.⁹⁴

Methodology for determining in vitro susceptibility to lincomycin

Susceptibility testing should be conducted using standardized laboratory methods, such as those described by the Clinical and Laboratory Standards Institute (CLSI) or the European Committee on Antimicrobial Susceptibility Testing (EUCAST). Because CLSI and EUCAST have not established susceptibility breakpoints for lincomycin, clindamycin should be tested instead. Resistance to lincosamides may be inducible by macrolides in macrolide-resistant staphylococci, *Streptococcus pneumoniae*, and beta-hemolytic streptococci. Macrolide-resistant isolates of these organisms should be screened for inducible clindamycin resistance using the D-zone test or other standard methodology.⁹⁴

CLSI dilution and disk diffusion susceptibility interpretive criteria for clindamycin⁹⁴

Organism	Susceptibility Interpretive Criteria					
	Minimal Inhibitory Concentrations (MIC in µg/mL)			Disk Diffusion (Zone Diameters in mm)		
	S	I	R	S	I	R
<i>Staphylococcus</i> spp.	≤0.5	1–2	≥4	≥21	15–20	≤14
<i>Streptococcus pneumoniae</i> , β-hemolytic streptococci and viridans group streptococci	≤0.25	0.5	≥1	≥19	16–18	≤15
Anaerobic Bacteria	≤2	4	≥8	NA	NA	NA
Disk content 2 µg. MIC interpretive criteria for anaerobes are based on agar dilution. NA=not applicable.						

The validity of both the dilution and disk diffusion test methods should be verified using quality control (QC) strains, as indicated by CLSI. Acceptable limits when testing clindamycin against these organisms are listed in the table below.⁹⁴

Quality control ranges for clindamycin susceptibility tests (CLSI)⁹⁴

Organism	Minimum Inhibitory Concentration Range (MIC in µg/mL)	Disk Diffusion Range (Zone Diameters in mm)
<i>Staphylococcus aureus</i> ATCC 29213	0.06–0.25	NA
<i>Staphylococcus aureus</i> ATCC 25923	NA	24–30
<i>Streptococcus pneumoniae</i> ATCC 49619	0.03–0.12	19–25
<i>Bacteroides fragilis</i> ATCC 25285	0.5–2	NA
<i>Bacteroides thetaiotaomicron</i> ATCC 29741	2–8	NA
<i>Eggerthella lenta</i> ATCC 43055	0.06–0.25	NA

MIC ranges for anaerobic bacteria are based on agar dilution.
NA=Not applicable
ATCC [®] is a registered trademark of the American Type Culture Collection

EUCAST dilution and disk diffusion susceptibility interpretive criteria for clindamycin⁹⁴

Organism	Minimal Inhibitory Concentrations (MIC in µg/mL)		Disk Diffusion (Zone Diameters in mm)	
	S	R	S	R
<i>Staphylococcus</i> spp.	≤0.25	>0.5	≥22	<19
<i>Streptococcus</i> groups A, B, C, G	≤0.5	>0.5	≥17	<17
<i>Streptococcus pneumoniae</i>	≤0.5	>0.5	≥19	<19
Viridans group streptococci	≤0.5	>0.5	≥19	<19
Gram-positive anaerobes (except <i>Clostridium difficile</i>)	≤4	--	NA	NA
Gram-negative anaerobes	≤4	--	NA	NA

Disk content 2 µg.
MIC interpretive criteria for anaerobes are based on agar dilution.
NA=not applicable.

Quality control ranges for clindamycin susceptibility tests (EUCAST)

Organism	Minimum Inhibitory Concentration Range (MIC in µg/mL)	Disk Diffusion Range (Zone Diameters in mm)
<i>Staphylococcus aureus</i> ATCC 29213	0.06–0.25	23-29
<i>Streptococcus pneumoniae</i> ATCC 49619	0.03–0.12	22-28

NA=Not applicable
ATCC[®] is a registered trademark of the American Type Culture Collection

Antibacterial Spectrum

The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.⁹⁴

Lincomycin is cross-resistant with clindamycin. A decrease in clindamycin/lincomycin susceptibility over time has been noted in particular among methicillin-resistant *Staphylococcus aureus* and in some species of *Clostridium*.⁹⁴

Organisms that are commonly susceptible to lincomycin include:⁹⁴

Aerobic and facultative gram-positive bacteria:

- *Staphylococcus aureus* (methicillin-susceptible strains only); *Streptococcus pneumoniae*; *Streptococcus pyogenes*; viridans group streptococci; *Corynebacterium diphtheriae*.

Anaerobic and microaerophilic bacteria:

- *Clostridium perfringens*; *Clostridium tetani*; *Propionibacterium acnes*.

5.2. PHARMACOKINETIC PROPERTIES

Oral administration of a single 500 mg dose of lincomycin in the fasting state produces an average peak serum level of 5.3 µg/mL at 2 hours post-dose. Administration immediately after a meal reduces oral absorption.^{44,94}

Intramuscular administration of a single dose of 600 mg of lincomycin produces average peak serum levels of 11.6 µg/mL at 60 minutes and maintains therapeutic levels for 17 to 20 hours for most susceptible gram-positive organisms.⁷⁸ Urinary excretion after this dose ranges from 1.8 to 24.8 percent (mean: 10.3 percent).^{44,78}

A two hour intravenous infusion of 600 mg of lincomycin achieves average peak serum levels of 15.9 µg/mL and yields therapeutic levels for 14 hours for most susceptible gram-positive organisms.⁷⁸ Urinary excretion ranges from 4.9 to 23.3 percent (mean: 15.1 percent).⁴⁴

The biological half-life after intramuscular administration is approximately 5 hours.^{77,79} The serum half-life of lincomycin may be prolonged in patients with severe impairment of renal function compared to patients with normal renal function.⁷⁹ In patients with abnormal hepatic function, serum half-life may be two-fold longer than in patients with normal hepatic function.⁸⁰ Hemodialysis and peritoneal dialysis are not effective in removing lincomycin from the serum.^{79,94}

Tissue level studies indicate that bile is an important route of excretion. Significant levels have been demonstrated in the majority of body tissues. Although lincomycin appears to diffuse into cerebrospinal fluid (CSF), levels of lincomycin in the CSF appear inadequate for the treatment of meningitis.^{44,45,81,94}

5.3. PRECLINICAL SAFETY DATA

Nonclinical data from conventional studies on repeated administration toxicity, genotoxicity,^{82,84,85,86,87,88,89,90,91,92,93,94,95} carcinogenesis,⁸³ and reproductive and developmental toxicity have not identified any particular risks to humans. No developmental toxicity was observed when doses greater than 6x the maximum recommended human dose (MRHD) were administered to pregnant rats during the organogenesis period.⁵⁵ No effects on fertility were observed in rats administered lincomycin at 1.2x the MRHD.^{48,49,94,95}

6. PHARMACEUTICAL PARTICULARS

6.1. LIST OF EXCIPIENTS

Information not available

6.2. INCOMPATIBILITIES

When combined with lincomycin in an infusion solution, novobiocin, kanamycin, and phenytoin are each physically incompatible with lincomycin.⁵⁸

6.3. SHELF LIFE

LINCOCIN[®] Injection: 36 months

LINCOCIN[®] Syrup: 24 months

LINCOCIN[®] Capsules: 36 months

6.4. SPECIAL PRECAUTIONS FOR STORAGE

Store at controlled room temperature 15°C-30°C.

6.5. NATURE AND CONTENTS OF CONTAINER

LINCOCIN[®] is available as:

- LINCOCIN[®] Injection 300 mg/mL in 5's (vials)
- LINCOCIN[®] Injection 600 mg/2 mL in 5's (vials)
- LINCOCIN[®] Capsules 500 mg in 12's blister pack
- LINCOCIN[®] Syrup 250 mg/5 mL in 60 mL bottle

Lincocin/LPD/PK05

According to CDS V 03 dated: February 13, 2018; Supersedes CDS V 02 dated: May 10, 2017

Manufactured by:

Pfizer Pakistan Limited B-2 S.I.T.E., Karachi

7. REFERENCES

1. LINCOMYCIN hydrochloride NDA, Supplement II, Volume II, Part 2: Clinical Summary, May 1964.
2. Lincocin Progress Report I and LINCOCIN (lincomycin hydrochloride) Clinical Expert Report. PD Eleftheriou, September 30, 1992.
3. Lincocin Progress Report II and LINCOCIN (lincomycin hydrochloride) Clinical Expert Report. PD Eleftheriou, September 30, 1992.
4. Lincocin Progress Report III and LINCOCIN (lincomycin hydrochloride) Clinical Expert Report. PD Eleftheriou, September 30, 1992.
5. Trakas JC and Lind HE; LINCOMYCIN in Ear, Nose, and Throat Infections. *Antimicrob Agents Chemother*, pp. 216-219, 1963.
6. Trakas JC and Lind HE; LINCOMYCIN, A New Antibiotic in Otolaryngological Infections. *The Eye, Ear, Nose & Throat Monthly* 44:46-50, Dec. 1965.
7. Moyer SK; Tabulation of Medical Literature Concerning Selected Uses of LINCOMYCIN. Memo to M. Hernandez, March 22, 1976, The Upjohn Company.
8. Harnecker J, Gilabert B, Contreras J, *et al.*; Preliminary Clinical-Bacteriological Study of a New Antibiotic: LINCOMYCIN. Treatment of 15 Cases of Diphtheria as Compared to 8 Cases Treated with Erythromycin. *Rev Chile Pediat* 34:522-528, 1963.
9. Harnecker J, Contreras J, Gilabert B, Ubilla V; Bacteriological and Clinical Studies of LINCOMYCIN Hydrochloride. *Antimicrob Agents Chemother* 1963:204-209 (Pub. 1964).
10. Walters EW, Romansky MJ and Johnson AC; LINCOMYCIN: Laboratory and Clinical studies. *Antimicrob Agents Chemother*, pp. 210-215, 1963.
11. Ory EM; A Summary of Clinical Experience with Lincocin. Oral Presentation, Brook Lodge Conference on LINCOMYCIN, August 24, 1964.
12. Romansky MJ, Johnson AC, Cohen P and Walters EW; Laboratory and Clinical Evaluation of LINCOMYCIN. Oral Presentation, Brook Lodge Conference on LINCOMYCIN, August 24, 1964.
13. Wunderly JE; The Clinical Use of Lincocin in Anaerobic Infections. Final report, The Upjohn Company, May 16, 1978.
14. Wunderly JE; The Clinical Use of Lincocin S.S. in Anaerobic Infections. Vols. I and II, December 30, 1974.
15. Wunderly JE; Parenteral and Oral Lincocin in the Treatment of Anaerobic Infections. Vols, I and II. July 15, 1975.
16. Wunderly JE; Lincocin in Anaerobic Infections. Update 1976. October 5, 1976.

17. Wunderly JE; Lincocin in the Treatment of Anaerobic Infections. August 1977 Update, August 31, 1977.
18. Prigot A; Studies with LINCOMYCIN. Oral Presentation, Brook Lodge Conference on LINCOMYCIN, August 24, 1964.
19. Kanee B; LINCOMYCIN in Dermatologic Practice. Can Med Assoc J 93:220-222, July 31, 1965.
20. Nierman MM; LINCOMYCIN in Management of Bacterial Dermatoses. Clinical Medicine 73:79-80, May 1966.
21. Geddes AM, Sleet RA and Murdoch JMcC; LINCOMYCIN Hydrochloride: Clinical and Laboratory Studies. Br Med J 2:660-664, September 12, 1964.
22. Herrell WE; LINCOMYCIN in the Treatment of Staphylococcal Osteomyelitis. Clinical Medicine, pp. 17-19, May 1968.
23. Blastenie PA, Linz R, Spehl P; The Place of LINCOMYCIN in the Treatment of Streptococcal Endocarditis Concerning Four Cases. Extract from Acta Cardiologica, Vol. XXV, Section 1, pp. 51-57, 1970.
24. Panzer JD and Atkinson WH; Lincocin IV in Subacute Bacterial Endocarditis. Final Report, The Upjohn Company, issued March 9, 1971.
25. Kaplan K, Chew WH and Weinstein L: Microbiological, Pharmacological and Clinical Studies of LINCOMYCIN. The American Journal of the Medical Sciences 250(2):55/137-64/146, August 1965.
26. Naita D, *et al*; Treatment of Bacterial Excretion in Bacillary Dysentery with LINCOMYCIN (Lincocin). Chemotherapy, p. 592, September 1967.
27. Nakazawa S, *et al*; Clinical Response to LINCOMYCIN in Bacillary Dysentery. Showa University, p. 416.
28. Tajimi H, *et al*; Various Antibiotic Therapies, in Bacillary Dysentery. 1967, Lincocin Compendium, Unit 9126.
29. Bartlett JG, *et al*; Antibiotic Associated Pseudomembranous Colitis Due to Toxin-Producing Clostridia. N Engl J Med 298(10):531-534, 1978.
30. George RH, *et al*; Identification of Clostridium difficile as a Cause of Pseudomembranous Colitis. Br Med J 6114:669-671, 1978.
31. Larson HE, Price, AB; Pseudomembranous Colitis Presence of Clostridial Toxin. Lancet 8052/3:1312-1314, 1977.
32. Bartlett JG; Antimicrobial-Associated Gastroenteritis. Ann Roy Coll Phys Surg Can 13:32-35, 1980.
33. Meuwissen SGM and Rietra PJ; Antibiotic-Associated Pseudomembranous Colitis: A Progress Report. Acta Gastro-Enterol Belg. 43:377-385, 1980.

34. Fekety R; Antibiotic-Associated Colitis - Revisited. Clin Micro Newsletter 3:63-65, 1981.
35. Roddis MJ; Antibiotic-Associated Colitis: A Retrospective Study of Fifteen Cases. Age Aging 7:182-188, 1978.
36. Burbige EJ and Milligan FD; Pseudomembranous Colitis-Association with Antibiotics and Therapy with Cholestyramine. JAMA 231:1157-1158, 1975.
37. Kreutzer EW and Milligan FD; Treatment of Antibiotic-Associated Pseudomembranous Colitis with Cholestyramine Resin. Johns Hopkins Med J 143:67-72, 1978.
38. Schussheim A and Goldstein EJC; Antibiotic-Associated Pseudomembranous Colitis in Siblings. Pediatrics 66:932-935, 1980.
39. Viscidi RP and Barlett JG; Antibiotic-Associated Pseudomembranous Colitis in Children. Pediatrics 67:381-386, 1981.
40. Tedesco FJ, Napier J, *et al*; Therapy in Antibiotic Associated Pseudomembranous Colitis. J Clin Gastroenterol 1:51-54, 1979.
41. Keighley MRB, Burdon DW, *et al*; Randomized Controlled trial of Vancomycin for Pseudomembranous Colitis and Postoperative Diarrhea. Br Med J 2:1667-1669, 1978.
42. Chang T-W, Gorbach SL, *et al*; Bacitracin Treatment of Antibiotic-Associated Colitis and Diarrhea Caused by Clostridium difficile Toxin. Gastroenterology 78:1584-1586, 1980.
43. Novak E, Lee JG, *et al*; Unfavorable Effect of Atropine-Diphenoxylate (Lomotil) Therapy in LINCOMYCIN-Caused Diarrhea. JAMA 235:1451-1454, 1976.
44. Medina A, Fiske N, *et al*; Absorption, Diffusion, and Excretion of a New Antibiotic, LINCOMYCIN. Antimicrob Agents Chemother 1963:189-196, 1964.
45. Lerner PI; Penetration of Cephalothin and LINCOMYCIN into Cerebrospinal Fluid. Am J Med Sci 257:125-131, 1969.
46. Data on File. Upjohn Company. Adverse Drug Reaction Quarterly Report.
47. Finegold SM, Harada NE, *et al*; LINCOMYCIN: Activity Against Anaerobes and Effect on Normal Human Fecal Flora. Antimicrob Agents Chemother 1965:659-667, 1966.
48. Black DL, Poppe SM, Marks TA, *et al*. A two-generation reproduction study (oral) in rats given U-10149A. Upjohn Technical Report 7259-87-024, 27 January 1988.
49. Goyings LS, Thomas RW, VanHuysen CN, *et al*. Three generation reproductive study with premix and USP grades of lincomycin hydrochloride in Sprague-Dawley rats. Upjohn Technical Report 768-9610-79-001, 30 April 1979.
50. Samuelson RJ, Giesecke AH, *et al*; LINCOMYCIN-Curare Interaction. Anesth Analg 54:103-105, 1975.

51. Robbo JT, Gergis SD, *et al*; Comparative Neuromuscular Effects of LINCOMYCIN and Clindamycin. *Anesth Analg* 56:329-332, 1977.
52. Bellamy HM, Bates BB, *et al*; LINCOMYCIN Metabolism in Patients with Hepatic Insufficiency: Effect of Liver Disease on LINCOMYCIN Serum Concentrations. *Antimicrob Agents Chemother* 1966:36-41, 1967.
53. Bennett WM, Muther RS, *et al*; Drug Therapy in Renal Failure: Dosing Guidelines for Adults. Part 1: Antimicrobial Agents, Analgesics. *Ann Intern Med* 93:62-89, 1980.
54. Whelton A; Therapeutic Consideration in the Use of Antibiotics in Renal Insufficiency. *Obstet Gynecol* 5(Suppl.):128S-138S, 1980.
56. Duignan NM, Andrews J, Williams JD. Pharmacological studies with lincomycin in late pregnancy. *Br Med J* 1973;3:75-8.
57. Mickal A, Panzer JD. The safety of lincomycin in pregnancy. *Am J Obstet Gynecol* 1975;121(8):1071-4.
59. Letter from FDA issued 29 September 2006 (received 10 October 2006).
60. Wysowski DK. Increase in deaths related to enterocolitis due to *Clostridium difficile* in the United States, 1999-2002. *Public Health Reports* 2006;121:361-362.
61. *Clostridium difficile*: deaths increase in 2005. Deaths: Office for National Statistics, England and Wales. Available at: <http://www.statistics.gov.uk/cci/nugget.asp?id=1735> Accessed May, 2007.
62. McDonald LC, Killgore GE, Thompson A, Owens RC Jr, Kazakova SV, Sambol SP, *et al*. An epidemic, toxin gene-variant strain of *Clostridium difficile*. *N Engl J Med* 2005;353:2433-2441.
63. Loo VC, Poirier L, Miller MA, Oughton M, Libman, MD, Michaud S, *et al*. A predominantly clonal multi-institutional outbreak of *Clostridium difficile*-associated diarrhea with high morbidity and mortality. *N Engl J Med* 2005;353:2442-2449.
64. Chernak E, Johnson CC, Weltman A, McDonald LC, Wiggs L, Killgore G, *et al*. Severe *Clostridium difficile*-associated disease in populations previously at low risk-four states, 2005. *Morbidity and Mortality Weekly Report* 2005;54(47);1201-1205.
65. Pepin J, Valiquette L, Alary M-E, Villemure P, Pelletier A, Forget K, Pepin K, Chouinard D. *Clostridium difficile*-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. *CMAJ* 2004;171:466-472.
66. Morris AM, Jobe BA, Stoney M, Sheppard BC, Deveney CW, Deveney KE. *Clostridium difficile* colitis: an increasingly aggressive iatrogenic disease? *Arch Surg* 2002; 137:1096-1100.
67. McCusker ME, Harris AD, Perencevich E, Roghmann M-C. Fluoroquinolone use and *Clostridium-difficile* associated diarrhea. *Emerging Infect Dis* 2003;9:730-733.
68. Thomas C, Stevenson M, Williamson DJ, Riley TV. *Clostridium difficile*-associated diarrhea: epidemiological data from Western Australia associated with a modified antibiotic policy. *Clin Infect Dis* 2002;35:1457-1462.

69. D. Levy *et al*, Antibiotics and *C. difficile* Diarrhea in the Ambulatory Care Setting, *Clin. Therapeutics*, 2000; 22 (1): 91-102.
70. G. Cote and A. Buchman, Antibiotic-associated Diarrhea, *Expert Opin. Drug Saf.* (2006) 5(3):361-372.
71. Kuijper E., *et al*, Emergence of *Clostridium difficile*-associated disease in North America and Europe, *Clin Microbiol Infect* 2006; 12 (Suppl. 6): 2–18.
72. Gifford AH and Kirkland KB, Risk factors for *Clostridium difficile*-associated diarrhea on an adult hematology-oncology ward, *Eur J Clin Microbiol Infect Dis* (2006) 25:751–755.
73. Module 2.5 Clinical Overview: Benzyl Alcohol Excipient Warnings to support Multiple Product CDSs. Pfizer Inc.; September 2013.
74. Report of CIOMS Working Groups III and V, Guidelines for Preparing Core Clinical-Safety Information on Drugs, Second Edition.
75. October 2014_Lincomycin_2.5 Clinical Overview ADR Frequency Update_CDS Updates.
76. 2.5 Clinical Overview Benzyl Alcohol Excipient Restrictions to Support Multiple Product CDSs, October 2015.
77. Smith RB, Lummis WL, Monovich RE, DeSante KA. Lincomycin serum and saliva concentrations after intramuscular injection of high doses. *J Clin Pharmacol* 1981;21:411-417.
78. Vavra JJ, Sokolski WT, Lawson JB. Absorption and excretion of lincomycin hydrochloride in human volunteers. *Antimicrob Agents Chemother* 1963;161:176-82
79. Reinarz JA, McIntosh DA.: Lincomycin excretion in patients with normal renal function, severe azotemia, and with hemodialysis and peritoneal dialysis. *Antimicrob Agents Chemother* 1965; 232-8.
80. Bellamy HM Jr, Bates BB, Reinarz JA.: Lincomycin metabolism in patients with hepatic insufficiency: effect of liver disease on lincomycin serum concentrations. *Antimicrob Agents Chemother* 1967; :36-41.
81. Vacek V, Hejzlar M, Skalova M. Penetration of antibiotics into the cerebrospinal fluid in inflammatory conditions: 2. Lincomycin. *Int Z Klin Pharmakol Ther Toxikol* 1968; 1:501-3.
83. Aaron CS, Mazulex JH. Evaluation of U-10,149A (Lincomycin) in the Salmonella/microsome test (Ames Assay). Upjohn Technical Report 7268/87/016; 09 Nov 1987.
84. Mazurek JH, Swenson SH. Evaluation of U-10,149A in the Salmonella/Microsome test (Ames test). Upjohn Technical Report 9610/81/7263/001; 20 Aug 1981.
85. Harbach PR, Johnson MA, Bhuyan BK. The V-79 Mammalian Cell Mutation Assay with Lincomycin (U-10,149A). Upjohn Technical Report 9610/82/7263/001; 10 Feb 1982.

86. Harbach PR. The V-79 Mammalian cell mutation assay with lincomycin (U-10,149A) using an S9 activation system. Upjohn Technical Report 9610/82/7263/007; 17 Nov 1982.
87. Petzold GL. Evaluation of U-10,149A (Lincomycin-HCl) in the DAN damage/alkaline elution assay. Upjohn Technical Report 9610/81/7263/003; 23 Sep 1981.
88. Aaron CS. U-10149A: Evaluation of U-10149A (lincomycin) in an *in vitro* cytogenetics assay in human lymphocytes. Upjohn Technical Report 7228-91-081; 19 Dec 1991.
89. Trzos RJ, Swenson DH. The micronucleus test with lincomycin (U-10,149A). Upjohn Technical Report 9610/81/7263/002, 21 Aug 1981.
90. Aaron CS. U-10149A: Evaluation of U-10149A (lincomycin hydrochloride) in the micronucleus test in mouse bone marrow. Upjohn Technical Report 7228-91-088; 19 Dec 1991.
91. Aaron CS. Evaluation of lincomycin (U-10,149A, Lot# 647AF) in the Drosophila sex-linked recessive lethal assay. Upjohn Technical Report 7268/87/045; 19 Jan 1988.
92. Seaman WJ. Evaluation of lincomycin HCl (U-10149A) in the Primary Rat Hepatocyte Unscheduled DNA Synthesis Assay. Upjohn Technical Report 768-9610-82-001; 30 Nov 1982.
93. Harbach PR, Aaron CS. Evaluation of U-10,149A (Lincomycin) Lot #647AF in the *in vitro* unscheduled DNA synthesis (UDS) assay in rat primary hepatocytes. Upjohn Technical Report 7268/87/035; 23 Nov 1987.
94. Lincomycin_2.5 Clinical Overview_CDS Updates_To Support Updates to Sections of the CDS Based on the Updated CDS Template April 2017
95. 2014-03 PF-00345052 (Lincomycin) Envelope 2.4 NonClinical Overview to support the update for the Lincomycin Core Data Sheet (CDS), March 2015.
96. 2.5 Clinical Overview Updates to Sections 4.4 and 4.8 of the Core Data Sheet, February 2018.

Document Approval Record

Document Name: LPD Lincomycin - Lincocin (Pakistan)

Document Title: LPD Lincomycin - Lincocin (Pakistan)

Signed By:	Date(GMT)	Signing Capacity
Patel, Bushra Muzamil	13-Mar-2018 13:24:20	Regulatory Affairs Approval